Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Celyad Sa ADR (CYAD)

Celyad Sa ADR (CYAD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,619
  • Shares Outstanding, K 22,594
  • Annual Sales, $ 110 K
  • Annual Income, $ -9,140 K
  • 60-Month Beta 1.86
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CYAD with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 03/28/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4700 unch
on 05/18/23
0.8200 -42.68%
on 04/19/23
-0.3325 (-41.43%)
since 04/18/23
3-Month
0.4700 unch
on 05/18/23
1.2800 -63.28%
on 02/21/23
-0.7500 (-61.48%)
since 02/17/23
52-Week
0.4604 +2.09%
on 12/30/22
3.0700 -84.69%
on 01/18/23
-1.0800 (-69.68%)
since 05/18/22

Most Recent Stories

More News
Initiatives For Development of Gamma Delta T Cell Therapies Driven by Large Number of Clinical Trials

EQNX::TICKER_START (NASDAQ:TCBP),(NASDAQ:CRDF),(NASDAQ:CYAD),(NASDAQ:RIGL),(NASDAQ:AZN) EQNX::TICKER_END

TCBP : 1.5800 (unch)
TCBPW : 0.0209 (-22.59%)
CRDF : 4.17 (-4.36%)
CYAD : 0.4700 (-11.10%)
RIGL : 1.1400 (+0.88%)
AZN : 70.85 (+1.03%)
Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction

Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development...

CYAD : 0.4700 (-11.10%)
Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

Enrollment ongoing in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory (r/r)...

CYAD : 0.4700 (-11.10%)
Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial

MONT-SAINT-GUIBERT, Belgium, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company...

CYAD : 0.4700 (-11.10%)
Celyad Oncology to Announce First Half 2022 Financial Results and Host Conference Call

MONT-SAINT-GUIBERT, Belgium, July 28, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company...

CYAD : 0.4700 (-11.10%)
Celyad Oncology Announces Leadership Updates

MONT-SAINT-GUIBERT, Belgium, June 24, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage...

CYAD : 0.4700 (-11.10%)
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

MONT-SAINT-GUIBERT, Belgium, May 31, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage...

CYAD : 0.4700 (-11.10%)
Celyad SA (CYAD) Upgraded to Buy: Here's What You Should Know

Celyad SA (CYAD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CYAD : 0.4700 (-11.10%)
Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference

MONT-SAINT-GUIBERT, Belgium, May 17, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage...

CYAD : 0.4700 (-11.10%)
CORRECTION - Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights

MONT-SAINT-GUIBERT, Belgium, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Celyad Oncology SA (Euronext...

CYAD : 0.4700 (-11.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium.

See More

Key Turning Points

3rd Resistance Point 0.5667
2nd Resistance Point 0.5473
1st Resistance Point 0.5087
Last Price 0.4700
1st Support Level 0.4507
2nd Support Level 0.4313
3rd Support Level 0.3927

See More

52-Week High 3.0700
Fibonacci 61.8% 2.0731
Fibonacci 50% 1.7652
Fibonacci 38.2% 1.4573
Last Price 0.4700
52-Week Low 0.4604

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar